Recruiting

Observational Study

Sponsor:

University of Pittsburgh

Code:

NCT03273049

Conditions

Biliary Atresia

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

This project will primarily evaluate the developmental/genetic basis of biliary atresia, the most common cause of liver failure at birth, and which accounts of half of all liver transplants performed worldwide in children.

Conditions

Biliary Atresia

Study ID

NCT03273049

Start date

Jul 21, 2016

Status verified date

Aug, 2026

Completion date

Jul 21, 2035

Anticipated

Primary completion date

Dec 21, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • living individuals who were diagnosed with Biliary Atresia and received or are about to receive a liver transplant from multiple participating centers (Children's Hospital of Pittsburgh, Kings College Hospital, Children's Hospital of Birmingham, and Hospital Sírio-Libanês).

Exclusion Criteria:

  • No child participant in the care of the state will be enrolled, nor will patients in the care of temporary or informal guardians be enrolled

Study Design

Enrollment

1100 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Genomic pathways of BA [ Time Frame: up to two years ]

Central Contacts and Locations

Central contacts

Morgan L Paul, BSN

4126928472Morgan.Paul2@upmc.edu

Daniel Pieratt, MPA

4126926692pierattdw@upmc.edu

Locations

UPMC Children's Hospital of Pittsburgh

Recruiting

Pittsburgh, Pennsylvania, United States, 15224

Contacts

Morgan L Paul, BSN

412-692-8472Morgan.Paul2@upmc.edu

Daniel Pieratt, MPA

4126926692pierattdw@upmc.edu

Principal Investigator:

Rakesh Sindhi, MD

More Information

Sponsor

University of Pittsburgh

Last update posted

Aug 10, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Pittsburgh on 2026-08-10.